The International Chemical Biology Society (ICBS) has named Melvin Reichman, PhD President-Elect of the organization for the year 2014-2015. As President-Elect, Dr. Reichman will lead ICBS in expanding the mission of the Society and co-chair the 2015 Annual Meeting.
"It has been my privilege to help form and contribute to the growth of ICBS," comments Dr. Reichman. "My focus as President will be to encourage expansion of Society membership from international scientific communities and recruit active participation of scientists from chemical biology disciplines beyond pharmaceutical R&D. Partnerships with related societies and moving towards launching an ICBS journal will be exciting goals for us all.”
The International Chemical Biology Society was created in October of 2011 to serve an unmet need for an organization that would bring together researchers across disciplines and business sectors to germinate and nurture ideas that merge biology and chemistry. Dr. Reichman is also chairman of the board and an ICBS organizing committee member. He will assume the presidency of ICBS at the conclusion of their conference in November of 2014.
Dr. Reichman holds a PhD in Neuroscience from the University of Rochester Center for Brain Research, and has had a 20-year career in industry, holding leadership positions at GD Searle, Berlex Biosciences, Ligand Pharmaceuticals, and DuPont. He has been an invited expert on all aspects of drug discovery at more than 50 events worldwide. He has authored many peer-reviewed publications, has been a reviewer for many NIH study sections, and is an editor for several leading journals. A seasoned scientific advisor, Dr. Reichman lends his expertise to several start-up companies in the area of pharmaceutical research and development.
Currently, Dr. Reichman is the Founder, President and Chief Scientific Officer of LIMR Chemical Genomics Center, Inc. (LCGC), a biotech company that utilizes a patented automated repository and screening technology for accelerating drug discovery, including new approaches to discover synergistic combination-drugs.
ICBS is an independent, nonprofit organization dedicated to promoting research and educational opportunities at the interface of chemistry and biology. ICBS provides an important international forum that brings together cross-disciplinary scientists from academia, nonprofit organizations, government, and industry to communicate new research and help translate the power of chemical biology to advance human health. For more information, see the ICBS website at chemical-biology.org.
LCGC’s business model is a protected open-innovation framework called Double-Blinded Drug Discovery (DBD2) ® that establishes a new, public-private partnering consortium for drug-target translational research. The DBD2 model has been vetted by multiple non-profit and for-profit entities, including eighteen (18) international academic organizations, at current, with many more institutions in the process of coming on board. LCGC is a for-profit biotech company wholly owned by Lankenau Institute for Medical Research (LIMR), an independent, nonprofit biomedical research center located in suburban Philadelphia on the campus of Lankenau Medical Center, Main Line Health. Visit LCGC at lcgcinc.com.
© 2016 Main Line Health